Circulatory Cytokine Profiles of Ischemic Stroke Patients after Treatment with strowell capsules

Phase 2

Completed

• Conditions: Ischemic stroke.; Cerebral infarction, unspecified; I63.9

• Registration Number: IRCT20170315033086N5
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Diagnosis, based on neurological diagnostic signs and confirmed by Magnetic Resonance Imaging (MRI)
National Institutes of Health Stroke Scale (NIHSS) should be in 4 - 20 range at the time of admission.
Body mass index (BMI) should be in 20-25 range
No inflammatory diseases

Exclusion Criteria

Hemorrhagic stroke
transient ischemic attack (TIA)
History of gastrointestinal bleeding
History of sensitivity to NSIADs
Previous stroke
Myocardial infarction within the previous 48 hours
Kidney and liver failure
Immunosuppressive medications
Stroke patients who have received tissue plasminogen activator (tPA).
Rheumatoid and autoimmune diseases
Malignancies
Pregnancy or lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stroke intensity. Timepoint: At the commencement of the investigation and after taking the strowell capsules. Method of measurement: NIH Stroke Scale questionnaire for quantifying stroke severity (11 items are included, level of consciousness, horizontal eye movement, visual field test, facial palsy, motor arm and motor leg, limb ataxia, sensory, language, speech, extinction and inattention).;Pro- and anti-inflammatory plasma markers. Timepoint: At the investigation commencement and after the intervention. Method of measurement: ELISA assay kit.